Overview: Toxoplasma Gondii Qualitative PCR TestIntroduction: The Toxoplasma Gondii Qualitative PCR Test detects toxoplasma DNA to diagnose active infection, causing vision issues. Aligned with 2023 CDC guidelines, it uses PCR for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for immunocompromised or pregnant patients. Note: No specific test parameters provided in input data.
Other Names: Toxoplasma PCR Assay, Toxoplasma DNA Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Toxoplasma PCR testing began in the 1990s with infection research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects toxoplasma DNA to diagnose active infection, guides treatment, and evaluates patients with vision issues.
Test Parameters: Not specified in input data; typically includes toxoplasma DNA detection.
Pretest Condition: No fasting required. Collect whole blood, serum, plasma, CSF, amniotic fluid, or saliva. Report history of vision issues or toxoplasmosis exposure.
Specimen: Whole Blood (EDTA, 2-5 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), CSF (sterile container, 1-2 mL), Amniotic Fluid (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision issues, pregnancy, or immunocompromised status. Include current medications, especially antiparasitics.
Consent: Written consent required, detailing the tests purpose, toxoplasmosis implications, and risks of sample collection.
Procedural Considerations: Uses qualitative PCR to detect toxoplasma DNA. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for active infection diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Positive toxoplasma DNA confirms active infection, guiding antiparasitic therapy. Negative results may require serology or repeat PCR.
Specialist Consultation: Consult an infectious disease specialist or ophthalmologist for result interpretation and treatment planning.
Additional Supporting Tests: Toxoplasma IgM, IgG, or avidity testing to confirm infection status.
Test Limitations: Non-specific for infection stage; clinical correlation is needed. Sample quality affects sensitivity.
References: CDC Toxoplasmosis Guidelines, 2023; Clinical Infectious Diseases, Dard C, 2022.
